Huperzine a inhibits CCL2 production in experimental autoimmune encephalomyelitis mice and in cultured astrocyte

International Journal of Immunopathology and Pharmacology

Volumn 26, Issue 3, 2013, Pages 757-764

  Tian, G X ^a   Zhu, X Q ^a   Chen, Y ^a   Wu, G C ^a   Wang, Jun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Astrocyte; CCL2; Experimental autoimmune encephalomyelitis; Huperzine A; PPAR ; Pro inflammatory cytokines

Indexed keywords

HUPERZINE A; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; FEMALE; IN VITRO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD;

ALKALOIDS; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; PPAR GAMMA; SESQUITERPENES; SIGNAL TRANSDUCTION; SPINAL CORD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887438080     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201302600320     Document Type: Article

References (19)

1. Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007; 115:137-46. (Pubitemid 46219205)
2. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010; 120:1368-79.
3. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, De Groot CJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999; 154:45-51. (Pubitemid 29031610)
4. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010; 224:93-100.
5. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86:20-9. (Pubitemid 28293946)
6. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000; 108:192-200. (Pubitemid 30438767)
7. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192:899-905.
8. Eltayeb S, Berg AL, Lassmann H, Wallstrom E, Nilsson M, Olsson T, Ericsson-Dahlstrand A, Sunnemark D. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J Neuroinflammation 2007; 4:14.
9. Castellani ML, Bhattacharya K, Tagen M, et al. Anti-chemokine therapy for inflammatory diseases. Int J Immunopathol Pharmacol 2007; 20:447-53. (Pubitemid 47534148)
10. Wang J, Chen F, Zheng P, et al. Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T-cell-mediated neuronal inflammation in mice. Exp Neurol 2012; 236:79-87.
11. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192:1075-80.
12. Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998; 92:98-108. (Pubitemid 29015994)
13. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 2009; 41:998-1001.
14. Hayashi M, Luo Y, Laning J, Strieter RM, Dorf ME. Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells. J Neuroimmunol 1995; 60:143-50.
15. Zhang HY. New insights into huperzine A for the treatment of Alzheimer's disease. Acta Pharmacol Sin 2012; 33:1170-5.
16. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem 2008; 106:506-18.
17. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res 2008; 2008:658520.
18. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005; 161:113-22. (Pubitemid 40340879)
19. Peng Y, Li Q, Zhang L, Bai M, Zhang Z. Peroxisome proliferator-activated receptor alpha plays an important role in the expression of monocyte chemoattractant Protein-1 and neointimal hyperplasia after vascular injury. PPAR Res 2012; 2012:970525.